Further EWAS studies with larger sample sizes in those with APOL1 high-risk genotypes, as well as use of DNA methylation derived from kidney tissue will improve our understanding of the regulatory mechanisms of CKD in APOL1 high-risk genotypes and hopefully shed more light on the pathophysiological mechanisms of APOL1 nephropathy. This evidence concerns the gene APOL1 and kidney disorder.